Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

What Investors Should Look For In Vaccine Trials' Raw Data

By Corinne Cardina - Nov 21, 2020 at 8:56AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Dr. Leo Nissola shares what more he wants to see from Pfizer and Moderna as they move toward submitting their potential vaccines to the FDA.

Pfizer ( PFE -0.62% ) and its German partner BioNTech ( BNTX -3.55% ) reported incredible efficacy data from a phase 3 trial for their mRNA coronavirus vaccine candidate. This news, paired with the equally impressive data from Moderna ( MRNA 0.37% ) about its candidate that takes a similar approach, inspired much hope around the world and injected optimism into the stock market.

The Motley Fool talked to Dr. Leo Nissola about what this exciting development means for the world and what investors should be looking for as more data comes out.

 

 

Cardina: As I said, it is very preliminary. Are there any specific data points that you're going to be watching when more of Pfizer's data comes out and it is peer-reviewed?

Nissola: Of course. Yeah. Well, they have send out test release based on the 94 confirmed cases of COVID-19 at their interim analysis, we have yet to see the published study results. We want to see the raw data, we want to see the paper being peer-reviewed. We want to just make sure that we are on board with the fantastic news. There's nothing out there that has been proven to work so far. Although, we have 38 great candidates in Phase 1 studies and 11 in Phase 2. Anything that works, it's good news out. First, is results from this Phase 3 trial has to be seen in the context of how you came about. Preclinically, Pfizer had shown results that their vaccine worked in non-human primates. In early clinical trials, their vaccine induced good neutralizing antibody responses. That's what this vaccine does well. Now, in addition to that, we get interim efficacy results that are in the 90% range. Any percentage's pretty good. It might be even higher, but we haven't seen the data, so it can potentially be lower too. It's very important to manage expectations there.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$51.40 (-0.62%) $0.32
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$283.40 (0.37%) $1.05
BioNTech SE Stock Quote
BioNTech SE
BNTX
$291.94 (-3.55%) $-10.75

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
652%
 
S&P 500 Returns
142%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/08/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.